Zoetis (ZTS) Assets Average (2013 - 2026)
Zoetis' (ZTS) quarterly Assets Average came in at $15.3 billion in Q1 2026, up 8.29% year-on-year from $14.1 billion in Q1 2025, and little changed on a QoQ basis from $15.3 billion in Q4 2025.
Zoetis (ZTS) Assets Average (2013 - 2026) Analysis & Trends
Zoetis (ZTS) has 14 years of Assets Average data on file, last reported at $15.3 billion in Q1 2026.
- On a quarterly basis, Assets Average rose 8.29% year-over-year to $15.3 billion in Q1 2026; TTM through Mar 2026 was $15.3 billion, a 8.29% increase from a year earlier, with the FY2025 full-year figure at $14.8 billion, up 4.23% from the prior year.
- Assets Average for Q1 2026 stood at $15.3 billion, roughly flat from $15.3 billion in the prior quarter.
- Over the last five years, Assets Average for ZTS reached as high as $15.3 billion in Q4 2025 and fell as low as $13.7 billion in Q3 2022.
- Historically, Assets Average has averaged $14.3 billion across 5 years, with a median of $14.3 billion in 2024.
- Across the five-year window, Assets Average retreated 1.19% in 2022 and grew 8.29% in 2026, its largest moves.
- Year by year, Assets Average stood at $14.3 billion in 2022, then slipped by 0.72% to $14.2 billion in 2023, then rose by 0.58% to $14.3 billion in 2024, then advanced by 7.33% to $15.3 billion in 2025, then dropped by 0.02% to $15.3 billion in 2026.
- Per Business Quant data, the three most recent Assets Average figures were $15.3 billion in Q1 2026, $15.3 billion in Q4 2025, and $14.8 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | 43.72 Bn |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | 40.39 Bn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | 15.32 Bn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | 99.52 Bn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 7.30 Bn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | 21.86 Mn |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | 37.01 Bn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 4.77 Bn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | 13.29 Bn |
| 10 | Vireo Growth | 10.53 Bn | 10.38 Bn | 59.30 Mn | 873.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15.32 Bn |
| Dec 31, 2025 | 15.32 Bn |
| Sep 30, 2025 | 14.82 Bn |
| Jun 30, 2025 | 14.29 Bn |
| Mar 31, 2025 | 14.15 Bn |
| Dec 31, 2024 | 14.28 Bn |
| Sep 30, 2024 | 14.26 Bn |
| Jun 30, 2024 | 14.26 Bn |
| Mar 31, 2024 | 14.32 Bn |
| Dec 31, 2023 | 14.20 Bn |
| Sep 30, 2023 | 13.93 Bn |
| Jun 30, 2023 | 13.75 Bn |
| Mar 31, 2023 | 14.34 Bn |
| Dec 31, 2022 | 14.30 Bn |
| Sep 30, 2022 | 13.72 Bn |
| Jun 30, 2022 | 13.82 Bn |
| Mar 31, 2022 | 13.88 Bn |
| Dec 31, 2021 | 13.80 Bn |
| Sep 30, 2021 | 13.89 Bn |
| Jun 30, 2021 | 13.93 Bn |